Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Deegan

Showing results (1-10 of 46) with videos related to

Pageof 5
Sort By:
Lancet (London, England)|May 4, 2010
Enzyme replacement therapy for Fabry's diseasePatrick Deegan
Acta Paediatrica (Oslo, Norway : 1992)|May 28, 2008
Gaucher disease: improving managementBruno Bembi, Patrick Deegan
Chemistry of Materials : a Publication of the American Chemical Society|June 25, 2026
Structure, Electrochemistry, and Phase Evolution of Al-Substituted Na<sub>2/3</sub>[Ni<sub>1/3‑y</sub>Mn<sub>2/3‑z</sub>Al <sub><i>y</i>+<i>z</i></sub> ]O<sub>2</sub> as a Sodium-Ion Battery Cathode MaterialAnthony T Pacileo, Patrick Deegan, Hao Liu
The Australasian Journal of Dermatology|April 16, 2013
Warfarin-induced calciphylaxis successfully treated with sodium thiosulphateJuber Hafiji, Patrick Deegan, Rebecca Brais, et al.
Orphanet Journal of Rare Diseases|February 19, 2021
The International Collaborative Gaucher Group GRAF (Gaucher Risk Assessment for Fracture) score: a composite risk score for assessing adult fracture risk in imiglucerase-treated Gaucher disease type 1 patientsPatrick Deegan, Aneal Khan, José Simon Camelo, et al.
Orphanet Journal of Rare Diseases|June 18, 2026
Multimodal phenotypic clustering predicts cardiac outcomes in Fabry diseaseElad Shemesh, Paul Feigin, Chong Yew Tan, et al.
British Journal of Haematology|September 8, 2009
Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosisPramod K Mistry, Patrick Deegan, Ashok Vellodi, et al.
Orphanet Journal of Rare Diseases|January 8, 2025
Clinical management of female patients with Fabry disease based on expert consensusEva Brand, Aleš Linhart, Patrick Deegan, et al.
Molecular Genetics & Genomic Medicine|November 17, 2025
Historical Control Analysis Demonstrates Greater Long-Term Reduction in Plasma Globotriaosylceramide (Gb3) by Venglustat Compared With Placebo or Agalsidase Beta in Male Patients With Classic Fabry DiseaseDominique P Germain, Pronabesh DasMahapatra, Shiguang Liu, et al.
The Cochrane Database of Systematic Reviews|March 28, 2015
Enzyme replacement and substrate reduction therapy for Gaucher diseaseElad Shemesh, Laura Deroma, Bruno Bembi, et al.
Pageof 5

Showing results (1-10 of 46) with videos related to

Sort By:
Pageof 5
Lancet (London, England)|May 4, 2010
Enzyme replacement therapy for Fabry's diseasePatrick Deegan
Acta Paediatrica (Oslo, Norway : 1992)|May 28, 2008
Gaucher disease: improving managementBruno Bembi, Patrick Deegan
Chemistry of Materials : a Publication of the American Chemical Society|June 25, 2026
Structure, Electrochemistry, and Phase Evolution of Al-Substituted Na<sub>2/3</sub>[Ni<sub>1/3‑y</sub>Mn<sub>2/3‑z</sub>Al <sub><i>y</i>+<i>z</i></sub> ]O<sub>2</sub> as a Sodium-Ion Battery Cathode MaterialAnthony T Pacileo, Patrick Deegan, Hao Liu
The Australasian Journal of Dermatology|April 16, 2013
Warfarin-induced calciphylaxis successfully treated with sodium thiosulphateJuber Hafiji, Patrick Deegan, Rebecca Brais, et al.
Orphanet Journal of Rare Diseases|February 19, 2021
The International Collaborative Gaucher Group GRAF (Gaucher Risk Assessment for Fracture) score: a composite risk score for assessing adult fracture risk in imiglucerase-treated Gaucher disease type 1 patientsPatrick Deegan, Aneal Khan, José Simon Camelo, et al.
Orphanet Journal of Rare Diseases|June 18, 2026
Multimodal phenotypic clustering predicts cardiac outcomes in Fabry diseaseElad Shemesh, Paul Feigin, Chong Yew Tan, et al.
British Journal of Haematology|September 8, 2009
Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosisPramod K Mistry, Patrick Deegan, Ashok Vellodi, et al.
Orphanet Journal of Rare Diseases|January 8, 2025
Clinical management of female patients with Fabry disease based on expert consensusEva Brand, Aleš Linhart, Patrick Deegan, et al.
Molecular Genetics & Genomic Medicine|November 17, 2025
Historical Control Analysis Demonstrates Greater Long-Term Reduction in Plasma Globotriaosylceramide (Gb3) by Venglustat Compared With Placebo or Agalsidase Beta in Male Patients With Classic Fabry DiseaseDominique P Germain, Pronabesh DasMahapatra, Shiguang Liu, et al.
The Cochrane Database of Systematic Reviews|March 28, 2015
Enzyme replacement and substrate reduction therapy for Gaucher diseaseElad Shemesh, Laura Deroma, Bruno Bembi, et al.
Pageof 5